Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy

Abel Decmann, Irina Bancos, Aakanksha Khanna, Melinda A. Thomas, Péter Turai, Pál Perge, József Zsolt Pintér, Miklós Tóth, A. Patócs, P. Igaz

Research output: Contribution to journalArticle

3 Citations (Scopus)


Introduction: Minimally invasive circulating microRNAs might be used for the preoperative differentiation of adrenocortical carcinoma (ACC) and adrenocortical adenoma (ACA). So far, the best blood-borne microRNA biomarker of ACC is circulating hsa-miR-483-5p. The expression of urinary hsa-miR-483-5p as a non-invasive marker of malignancy and its correlation with plasma hsa-miR-483-5p, has not been investigated, yet. Aim: Our aim was to investigate the expression of urinary hsa-miR-483-5p and its correlation with its plasma counterpart. Methods: Plasma and urinary samples from 23 ACC and 23 ACA patients were analysed using real-time RT-qPCR. To evaluate the diagnostic applicability of hsa-miR-483-5p, ROC-analysis was performed. Results: Significant overexpression of hsa-miR-483-5p was observed in carcinoma patients’ plasma samples compared to adenoma patients’ (p < 0.0001, sensitivity: 87%, specificity: 78.3%). In urinary samples, however, no significant difference could be detected between ACC and ACA patients. Conclusions: Plasma hsa-miR-483-5p has been confirmed as significantly overexpressed in adrenocortical cancer patients and thus might be exploited as a minimally invasive preoperative marker of malignancy. The applicability of urinary hsa-miR-483-5p for the diagnosis of adrenocortical malignancy could not be confirmed.

Original languageEnglish
Pages (from-to)49-53
Number of pages5
JournalJournal of Biotechnology
Publication statusPublished - May 20 2019



  • Adrenocortical cancer
  • microRNA
  • miR-483-5p
  • Plasma
  • Urinary

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this